Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Arch Gen Psychiatry ; 63(4): 450-6, 2006 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-16585475

RESUMEN

CONTEXT: Although the behavioral effects of high-dose androgen administration may involve alterations in serotonergic activity, few studies have investigated the impact of androgen withdrawal on the central nervous system in humans. OBJECTIVE: To examine the effects of pharmacologically induced hypogonadism on several cerebrospinal fluid (CSF) systems that could mediate the behavioral concomitants of hypogonadism. DESIGN: Double-blind assessment of the effects of the short-term induction of hypogonadism and subsequent replacement with testosterone and placebo in a crossover design. SETTING: National Institutes of Health, Bethesda, Md. PARTICIPANTS: Twelve healthy male volunteers. INTERVENTIONS: We administered the gonadotropin-releasing hormone agonist leuprolide acetate (7.5 mg intramuscularly every 4 weeks) to the healthy male volunteers, creating a hypogonadal state, and then either replaced testosterone (200 mg intramuscularly) or administered a placebo every 2 weeks for 1 month. MAIN OUTCOME MEASURES: Mood and behavioral symptoms were monitored with daily self-ratings, and lumbar punctures were performed during both hypogonadal (placebo) and testosterone-replaced conditions for CSF levels of steroids and monoamine metabolites. RESULTS: The CSF testosterone, dihydrotestosterone, and androsterone levels were significantly lower during hypogonadism (P=.002, .04, and .046, respectively), but no significant changes were observed in CSF measures of 5-hydroxyindoleacetic acid, homovanillic acid, dehydroepiandrosterone, or pregnenolone. Decreased sexual interest was observed during the hypogonadal state compared with both baseline and testosterone replacement (P=.009) and correlated significantly with CSF measures of androsterone during both hypogonadism and testosterone replacement (r = -0.76 and -0.81, respectively; P<.01). Moreover, the change in severity of decreased sexual interest correlated significantly with the change in CSF androsterone levels between testosterone replacement and hypogonadism (r = -0.68; P<.05). The CSF 5-hydroxyindoleacetic acid and homovanillic acid levels did not correlate significantly with any behavioral or CSF measure. CONCLUSION: These data suggest that the neurosteroid androsterone contributes to the regulation of sexual function in men.


Asunto(s)
Androsterona/fisiología , Hipogonadismo/inducido químicamente , Leuprolida/farmacología , Conducta Sexual/fisiología , Adolescente , Adulto , Afecto/efectos de los fármacos , Afecto/fisiología , Androsterona/sangre , Androsterona/líquido cefalorraquídeo , Androsterona/metabolismo , Estudios Cruzados , Dihidrotestosterona/sangre , Dihidrotestosterona/líquido cefalorraquídeo , Método Doble Ciego , Estradiol/sangre , Humanos , Hipogonadismo/sangre , Hipogonadismo/líquido cefalorraquídeo , Inyecciones Intramusculares , Leuprolida/administración & dosificación , Masculino , Persona de Mediana Edad , Radioinmunoensayo , Conducta Sexual/efectos de los fármacos , Punción Espinal , Testosterona/sangre , Testosterona/líquido cefalorraquídeo , Testosterona/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA